Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
Key Highlights
- ➤Germany grants full regulatory clearance for Anteris’ PARADIGM trial expansion
- ➤Patient recruitment can begin at leading German centers
- ➤PARADIGM trial targets approximately 1,000 randomized patients
- ➤Germany adds scale to the trial’s European enrollment strategy
Expert Statements
Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris
“Germany’s scale, clinical expertise and established TAVR infrastructure create an important opportunity to advance enrollment and extend PARADIGM’s reach across leading international TAVR markets”
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR(®) Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment at leading German centers and represents an important step in expanding the PARADIGM Trial’s European footprint.
Germany is Europe’s largest and most established transcatheter aortic valve replacement (TAVR) market, with an extensive network of experienced structural heart centers and investigators. Activating sites in this high-volume environment is anticipated to increase access to eligible patients and accelerate enrollment in the PARADIGM Trial.
Get started
Create a free account to read the full story.